UCB

Showing 15 posts of 80 posts found.

UCB’s Cimzia secures first-of-its-kind FDA approval in plaque psoriasis

May 29, 2018
Manufacturing and Production, Sales and Marketing Cimzia, FDA, UCB, US, pharma, psoriasis

The FDA has expanded the label for UCB’s Cimzia (certolizumab pegol) in the US, approving the therapy for the treatment …

FDA refuses approval of Amgen osteoporosis drug

July 17, 2017
Sales and Marketing Amgen, Evenity, Radial, UCB, biotech, drugs, osteoporosis, pharma, pharmaceutical

Amgen and its development partner UCB have announced that the FDA has issued a complete response letter for the biologics …

ucb_logo_pole2

US court rules in favour of UCB in patent dispute, shares jump

August 16, 2016
Manufacturing and Production, Research and Development, Sales and Marketing UCB, lacosamide, patent, vimpat

UCB has received a major boost after a Delaware district court confirmed the validity of the company’s patents on one …

Nice backs UCB’s Cimzia as alternate therapy for severe rheumatoid arthritis

July 13, 2016
Research and Development, Sales and Marketing Cimzia, NICE, UCB, regulation, rheumatoid arthritis

The National Institute for Health and Care Excellence (Nice) has recommended UCB Pharma’s Cimzia (certolizumab pegol) on its own or …

UCB scores Japanese approval for seizure therapy, Vimpat

July 5, 2016
Manufacturing and Production, Research and Development Daiichi Sankyo, Japan, UCB, japanese

UCB Biopharma (EURONEXT: UCB) and Daiichi Sankyo have announced that Vimpat (lacosamide) has been approved as an adjunctive therapy in …

tablet_production_2

Further positive trial results boost Amgen and UCB’s romosozumab

March 21, 2016
Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, clinical trial, osteoporosis, phase 3, phase III, regulatory approval

Amgen (NASDAQ:AMGN) and UCB (EBR:UCB) have announced positive top line results for romosozumab in men with osteoporosis in the Phase …

amgen_ucb

Amgen and UCB announce positive romosozumab results

February 22, 2016
Medical Communications, Research and Development, Sales and Marketing Amgen, Romosozumab, UCB, osteoporosis

Romosozumab development partners Amgen and UCB have announced positive top-line results from a Phase III study of the drug in postmenopausal …

AbbVie VP joins UCB Pharma

January 25, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Pascale Richetta, UCB, UCB Pharma

Pascale Richetta will join the UCB as its new head of the bone therapy patient value unit as from February …

steve_turley_linkedin

UCB appoints Steve Turley as MD for Britain and Ireland

November 18, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing UCB

Steve Turley has joined UCB as the company’s managing director for the British and Irish isles, moving from Lundbeck. He …

UCB plots new Vimpat submissions after positive monotherapy results

October 8, 2015
Research and Development EMA, European Medicines Agency, UCB, carbamazepine, epilepsy, lacosamide, phase III, vimpat

A Phase III non-inferiority study comparing UCB’s Vimpat with carbamazepine suggests the two drugs can be used as monotherapy treatments.  …

UCB

Mixed Phase 3 results for Sanofi and UCB

July 29, 2015
Research and Development LixiLan, Sanofi, UCB, clinical trials, epratuzumab, insulin, insulin glargine, phase III

Two drugs that pharma companies are pinning hopes on for future success have had mixed outcomes in key late-stage clinical …

Genome image

Big pharma teams with government on genomic research

March 27, 2015
Research and Development, Sales and Marketing AbbVie, Alexion Pharmaceuticals, AstraZeneca, Biogen, Cameron, Dimension Therapeutics, GSK, Genomic, Genomics england, Helomics, Roche, Takeda, UCB, UK, genomes

Ten firms will partner up with Genomics England to develop new diagnostics and treatments for people with rare diseases and …

UCB sponsors ‘Hack Epilepsy’ digital event

March 12, 2015
Medical Communications, Sales and Marketing Keppra, UCB, epilepsy, hack, lacosamide, levetiracetam, vimpat

Belgian biopharma firm UCB says it will be sponsoring a ‘Hack Epilepsy’ event this year to help support patient needs …

jean-christophe_tellier_ucb_ceo

UCB’s new chief executive picked as EU rep for MISG

February 25, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jean-Christophe Tellier, MISG, UCB

UCB’s newly-appointed chief executive Jean-Christophe Tellier has been selected to join the Ministerial Industry Strategy Group (MISG). Elected to the …

The Gateway to Local Adoption Series

Latest content